APOBEC3F
Apolipoprotein B mRNA Editing Enzyme Catalytic Subunit 3F
Gene Information Card
| Symbol | APOBEC3F |
|---|---|
| Full Name | Apolipoprotein B mRNA Editing Enzyme Catalytic Subunit 3F |
| Gene Type | Protein coding |
| Chromosomal Location | 22q13.1 |
| NCBI Gene ID | 200316 ncbi.nlm.nih.gov/gene/200316 |
| Ensembl ID | ENSG00000128394 |
| UniProt ID | Q8IUX4 |
| OMIM ID | 608993 |
| HGNC ID | 17356 |
| Aliases | A3F, ARP-9, MDS019, bK150C2.2 |
Description
APOBEC3F is a member of the apolipoprotein B mRNA editing enzyme catalytic polypeptide-like (APOBEC) family. It encodes a cytidine deaminase that catalyzes the deamination of cytosine to uracil in single-stranded DNA, playing a role in the innate immune response against retroviruses, including HIV-1. APOBEC3F is also implicated in cancer mutagenesis through aberrant DNA editing.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| HIV-1 Infection | APOBEC3F restricts HIV-1 replication by deaminating viral cDNA, but is counteracted by the HIV-1 Vif protein. | PMID: 15047845, PMID: 15280420 |
| Breast Cancer | APOBEC3F expression is elevated in breast tumors and contributes to APOBEC-signature mutations. | PMID: 23934620, PMID: 26689913 |
| Lung Cancer | APOBEC3F-mediated mutagenesis is observed in lung adenocarcinoma, linked to C-to-T transitions. | PMID: 26689913, PMID: 28270531 |
| Bladder Cancer | APOBEC3F is overexpressed in bladder cancer and associated with mutational signatures. | PMID: 26689913, PMID: 28270531 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Lymph Node | 10.2 | Medium |
| Spleen | 9.8 | Medium |
| Lung | 6.5 | Low |
| Breast | 4.1 | Low |
| Liver | 2.3 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HEK 293 | 12.5 | High expression |
| HeLa | 8.9 | Moderate expression |
| A549 | 6.2 | Low expression |
| MCF7 | 5.1 | Low expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1A>G (p.Met1?) | Missense | <0.01% | Likely loss of start codon; functional impact unknown |
| c.232C>T (p.Arg78Trp) | Missense | <0.01% | Reduced deaminase activity |
| c.1003G>A (p.Glu335Lys) | Missense | <0.01% | Unknown effect |
Mutation functional classification
Loss of Function (LOF)
Mutations that disrupt the catalytic domain (e.g., p.Arg78Trp) reduce cytidine deaminase activity.
Gain of Function (GOF)
No well-characterized gain-of-function mutations reported.
Dominant Negative (DN)
No dominant-negative mutations described.
View complete mutation data：
Gene Ontology (GO)
| • Cytidine deaminase activity (GO:0004126) | • Single-stranded DNA binding (GO:0003697) |
| • Zinc ion binding (GO:0008270) | • DNA deamination (GO:0045005) |
| • Defense response to virus (GO:0051607) | • Nucleus (GO:0005634) |
| • Cytoplasm (GO:0005737) |
Pathways
• Innate immune system (Reactome: R-HSA-168249)
• Antiviral mechanism by IFN-stimulated genes (Reactome: R-HSA-1169410)
• APOBEC-mediated mutagenesis in cancer (KEGG: hsa05200)
Protein Summary
APOBEC3F is a 373-amino acid protein containing a zinc-dependent cytidine deaminase domain. It localizes to the nucleus and cytoplasm, and functions as a homodimer. The protein catalyzes the deamination of cytosine to uracil in single-stranded DNA, restricting retroviral replication. In cancer, aberrant APOBEC3F activity leads to characteristic C-to-T and C-to-G mutation signatures.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| APOBEC3F Knockout HEK293 Cell Line | EDJ-KQ4453 | Human | 200316 | Details Get a Quote |
| APOBEC3F Knockout A-549 Cell Line | EDJ-KQ27007 | Human | 200316 | Details Get a Quote |
| APOBEC3F Knockout HCT 116 Cell Line | EDJ-KQ27008 | Human | 200316 | Details Get a Quote |
| APOBEC3F Knockout HeLa Cell Line | EDJ-KQ59004 | Human | 200316 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
